MDMA
Skeletal structure of racemic MDMA | |
Ball-and-stick model of MDMA | |
| Clinical data | |
|---|---|
| Pronunciation | methylenedioxymethamphetamine: /ˌmɛθɪliːndaɪˈɒksi/ /ˌmɛθæmˈfɛtəmiːn/ |
| Other names | 3,4-MDMA; Ecstasy (E, X, XTC); Midomafetamine; Molly; Mandy;[1][2] Pingers/Pingas[3] |
| AHFS/Drugs.com | MDMA |
| Dependence liability | Physical: Not typical[4] Psychological: Moderate[5] |
| Addiction liability | Low–moderate[6][7][8] |
| Routes of administration | Common: By mouth[9] Uncommon: Insufflation,[9] inhalation,[9] injection,[9][10] rectal |
| Drug class | Entactogen; Stimulant; Psychedelic; Serotonin–norepinephrine–dopamine releasing agent; 5-HT2 receptor agonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Oral: Unknown[13] |
| Protein binding | Unknown[14] |
| Metabolism | Liver, CYP450 extensively involved, including CYP2D6 |
| Metabolites | MDA, HMMA, HMA, HHMA, HHA, THMA, THA, MDP2P, MDOH[15] 3-MMOTI [16] |
| Onset of action | Oral: 30–45 min[13] |
| Elimination half-life | |
| Duration of action | 3–6 hours[19][7][13] |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO2 |
| Molar mass | 193.246 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| Density | 1.1 g/cm3 |
| Boiling point | 105 °C (221 °F) at 0.4 mmHg (experimental) |
| |
| |
| (verify) | |
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy in tablet form, and molly in crystal form,[20][21] is an entactogen with stimulant and minor psychedelic properties.[18][22][23]
MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch.[24] It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s.[25][26] MDMA is commonly used by attendees of dance parties, raves, and electronic dance music festivals.[27] Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine.[25]
The lethal risk from one dose of MDMA is estimated to be from 1 death in 20,000 instances to 1 death in 50,000 instances.[28]
The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure.[23][25] When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours.[13][26] Short-term adverse effects include bruxism, blurred vision, sweating, and tachycardia,[25] and extended use can also lead to addiction, amnesia, memory disorders, paranoia, and insomnia. Deaths have been reported due to increased body temperature and dehydration. MDMA acts primarily by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain.[25][26] It belongs to the substituted amphetamine classes of drugs.[9][29] MDMA is structurally similar to mescaline (a psychedelic), methamphetamine (a stimulant), as well as endogenous monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine.[30]
MDMA has limited approved medical uses in a small number of countries,[31] but is illegal in most jurisdictions.[32] MDMA-assisted psychotherapy may substantially improve PTSD symptoms, response, and remission rates compared to psychotherapy alone, but the evidence is low to very low certainty and safety data are limited, with some increased transient adverse events.[33] In the United States, the Food and Drug Administration (FDA) has given MDMA breakthrough therapy status (though there are no current clinical indications in the US).[34] Canada has allowed limited distribution of MDMA upon application to and approval by Health Canada.[35] In Australia, it may be prescribed in the treatment of PTSD by specifically authorised psychiatrists.[36]
Uses
Recreational
MDMA is often considered the drug of choice within the rave culture and is also used at clubs, festivals, and house parties.[15] In the rave environment, the sensory effects of music and lighting are often highly synergistic with the drug. The psychedelic amphetamine quality of MDMA offers multiple appealing aspects to users in the rave setting. Some users enjoy the feeling of mass communion from the inhibition-reducing effects of the drug, while others use it as party fuel because of the drug's stimulatory effects.[37] MDMA is used less often than other stimulants, typically less than once per week.[38]
MDMA is sometimes taken in conjunction with other psychoactive drugs such as LSD,[39] psilocybin mushrooms, 2C-B, and ketamine. The combination with LSD is called "candy-flipping".[39] The combination with 2C-B is called "nexus flipping". For this combination, most people take the MDMA first, wait until the peak is over, and then take the 2C-B.[40]
MDMA is often co-administered with alcohol, methamphetamine, and prescription drugs such as SSRIs with which MDMA has several drug–drug interactions.[41][42][43] Three life-threatening reports of MDMA co-administration with ritonavir have been reported;[44] with ritonavir having severe and dangerous drug–drug interactions with a wide range of both psychoactive, antipsychotic, and non-psychoactive drugs.[45]
Medical
Before it was widely banned, it saw limited use in psychotherapy.[7][9][46] In 2017 the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD).[47][48]
MDMA has limited approved medical uses in a small number of countries,[31] but is illegal in most jurisdictions.[32] Canada has allowed limited distribution of MDMA upon application to and approval by Health Canada.[35] In Australia, it may be prescribed in the treatment of PTSD by specifically authorised psychiatrists.[36]
Fourteen systematic reviews of up to 353 participants suggest MDMA-assisted psychotherapy may substantially improve PTSD symptoms, response, and remission rates compared to psychotherapy alone, but the evidence is low to very low certainty and safety data are limited, with some increased transient adverse events.[33]
Some researchers have proposed that psychedelics in general may act as active "super placebos" used for therapeutic purposes.[49][50]
Others
Small doses of MDMA are used by some religious practitioners as an entheogen to enhance prayer or meditation.[51] MDMA has been used as an adjunct to New Age spiritual practices.[52]
Forms

MDMA has become widely known as ecstasy (shortened "E", "X", or "XTC"), usually referring to its tablet form, although this term may also include the presence of possible adulterants or diluents. The UK term "mandy" and the US term "molly" colloquially refer to MDMA in a crystalline powder form that is thought to be free of adulterants.[1][2][53] MDMA is also sold in the form of the hydrochloride salt, either as loose crystals or in gelcaps.[54][55] MDMA tablets can sometimes be found in a shaped form that may depict characters from popular culture. These are sometimes collectively referred to as "fun tablets".[56][57]
Partly due to the global supply shortage of sassafras oil—a problem largely assuaged by use of improved or alternative modern methods of synthesis—the purity of substances sold as molly have been found to vary widely. Some of these substances contain methylone, ethylone, MDPV, mephedrone, or any other of the group of compounds commonly known as bath salts, in addition to, or in place of, MDMA.[2][53][54][55] Powdered MDMA ranges from pure MDMA to crushed tablets with 30–40% purity.[9] MDMA tablets typically have low purity due to bulking agents that are added to dilute the drug and increase profits (notably lactose) and binding agents.[9] Tablets sold as ecstasy sometimes contain 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), other amphetamine derivatives, caffeine, opiates, or painkillers.[7] Some tablets contain little or no MDMA.[7][9][58] The proportion of seized ecstasy tablets with MDMA-like impurities has varied annually and by country.[9] The average content of MDMA in a preparation is 70 to 120 mg with the purity having increased since the 1990s.[7]
MDMA is usually consumed by mouth. It is also sometimes snorted.[25]
Effects and side effects

Effects
In general, MDMA users report feeling the onset of subjective effects within 30 to 60 minutes of oral consumption and reaching peak effect at 75 to 120 minutes, which then plateaus for about 3.5 hours.[59] The desired short-term psychoactive effects of MDMA have been reported to include:
- Euphoria/ecstasy – a sense of general well-being and happiness[23][60]
- Increased self-confidence, sociability, and perception of facilitated communication[7][23][60]
- Entactogenic effects—increased empathy or feelings of closeness with others[23][60] and oneself[7]
- Dilated pupils[7]
- Relaxation and reduced anxiety[7]
- Increased emotionality[7]
- A sense of inner peace[60]
- Mild hallucination[60]
- Enhanced sensation, perception, or sexuality[7][23][60]
- Altered sense of time[26]
The experience elicited by MDMA depends on the dose, setting, and user.[7] The variability of the induced altered state is lower compared to other psychedelics. For example, MDMA used at parties is associated with high motor activity, reduced sense of identity, and poor awareness of surroundings. Use of MDMA individually or in small groups in a quiet environment and when concentrating, is associated with increased lucidity, concentration, sensitivity to aesthetic aspects of the environment, enhanced awareness of emotions, and improved capability of communication.[15][61] In psychotherapeutic settings, MDMA effects have been characterized by infantile ideas, mood lability, and memories and moods connected with childhood experiences.[61][62]
MDMA has been described as an "empathogenic" drug because of its empathy-producing effects.[63][64] Results of several studies show the effects of increased empathy with others.[63] When testing MDMA for medium and high doses, it showed increased hedonic and arousal continuum.[65][66] The effect of MDMA increasing sociability is consistent, while its effects on empathy have been more mixed.[67]
Side effects
Short-term
Acute adverse effects are usually the result of high or multiple doses, although single dose toxicity can occur in susceptible individuals.[23] The most serious short-term physical health risks of MDMA are hyperthermia and dehydration.[60][68] Cases of life-threatening or fatal hyponatremia (excessively low sodium concentration in the blood) have developed in MDMA users attempting to prevent dehydration by consuming excessive amounts of water without replenishing electrolytes.[60][68][28]
The immediate adverse effects of MDMA use can include:
- Bruxism (grinding and clenching of the teeth)[7][15][23]
- Dehydration[15][60][68]
- Diarrhea[60]
- Erectile dysfunction[7][69]
- Hyperthermia[7][15][68]
- Increased wakefulness or insomnia[7][60]
- Increased perspiration and sweating[60][68]
- Increased heart rate and blood pressure[7][15][68]
- Increased psychomotor activity[7]
- Loss of appetite[7][58]
- Nausea and vomiting[23]
- Visual and auditory hallucinations (rarely)[7]
Other adverse effects that may occur or persist for up to a week following cessation of moderate MDMA use include:[58][23]
Physiological
Psychological
Long-term
There is consistent evidence of structural and functional deficits in MDMA users with high lifetime exposure.[72] These structural or functional changes appear to be dose dependent and may be less prominent in MDMA users with a lifetime exposure of less than 50 doses used and less than 100 tablets consumed. Nonetheless, moderate MDMA use may still result in neurotoxicity and what constitutes moderate use is not clearly established.[73]
Furthermore, it is not clear yet whether "typical" recreational users of MDMA (1 to 2 pills of 75 to 125 mg MDMA or analogue every 1 to 4 weeks) will develop neurotoxic brain lesions.[74] Long-term exposure to MDMA in humans has been shown to produce marked neurodegeneration in striatal, hippocampal, prefrontal, and occipital serotonergic axon terminals.[72][75] Neurotoxic damage to serotonergic axon terminals has been shown to persist for more than two years.[75] Elevations in brain temperature from MDMA use are positively correlated with MDMA-induced neurotoxicity.[15][72][73] However, most studies on MDMA and serotonergic neurotoxicity in humans focus more on heavy users who consume as much as seven times or more the amount that most users report taking. The evidence for the presence of serotonergic neurotoxicity in casual users who take lower doses less frequently is not conclusive.[76]
However, adverse neuroplastic changes to brain microvasculature and white matter have been observed to occur in humans using low doses of MDMA.[15][72] Reduced gray matter density in certain brain structures has also been noted in human MDMA users.[15][72] Global reductions in gray matter volume, thinning of the parietal and orbitofrontal cortices, and decreased hippocampal activity have been observed in long term users.[7] The effects established so far for recreational use of ecstasy lie in the range of moderate to severe effects for serotonin transporter reduction.[77]
Impairments in multiple aspects of cognition, including attention, learning, memory, visual processing, and sleep, have been found in regular MDMA users.[7][23][78][72] The magnitude of these impairments is correlated with lifetime MDMA usage[23][78][72] and are partially reversible with abstinence.[7] Several forms of memory are impaired by chronic ecstasy use;[23][78] however, the effects for memory impairments in ecstasy users are generally small overall.[79][80] MDMA use is also associated with increased impulsivity and depression.[7]
Serotonin depletion following MDMA use can cause depression in subsequent days. In some cases, depressive symptoms persist for longer periods.[7] Some studies indicate repeated recreational use of ecstasy is associated with depression and anxiety, even after quitting the drug.[81] Depression is one of the main reasons for cessation of use.[7]
At high doses, MDMA induces a response in the neuroimmune system that, through several mechanisms, increases the permeability of the blood–brain barrier, thereby making the brain more susceptible to environmental toxins and pathogens.[82][83][page needed] In addition, MDMA has immunosuppressive effects in the peripheral nervous system and pro-inflammatory effects in the central nervous system.[84]
MDMA may increase the risk of cardiac valvulopathy in heavy or long-term users due to activation of serotonin 5-HT2B receptors.[85][86] MDMA induces cardiac epigenetic changes in DNA methylation, particularly hypermethylation changes.[87]
Research links regular MDMA use to reduced grey matter volume, particularly in the hippocampus. Structural MRI scans show significant volume reductions in the hippocampus, specifically subregions such as CA1, which directly control memory formation.[88]
Reinforcement disorders
Approximately 60% of MDMA users experience drug withdrawal symptoms when they stop taking MDMA.[58] Some of these symptoms include fatigue, loss of appetite, depression, and trouble concentrating.[58] Tolerance to some of the desired and adverse effects of MDMA is expected to occur with consistent MDMA use.[58] A 2007 delphic analysis of a panel of experts in pharmacology, psychiatry, law, policing and others estimated MDMA to have a psychological dependence and physical dependence potential roughly three-fourths to four-fifths that of cannabis.[89]
MDMA has been shown to induce ΔFosB in the nucleus accumbens.[90] Because MDMA releases dopamine in the striatum, the mechanisms by which it induces ΔFosB in the nucleus accumbens are analogous to other dopaminergic psychostimulants.[90][91] Therefore, chronic use of MDMA at high doses can result in altered brain structure and drug addiction that occur as a consequence of ΔFosB overexpression in the nucleus accumbens.[91] MDMA is less addictive than other stimulants such as methamphetamine and cocaine.[92][93] Compared with amphetamine, MDMA and its metabolite MDA are less reinforcing.[94]
One study found approximately 15% of chronic MDMA users met the DSM-IV diagnostic criteria for substance dependence.[95] However, there is little evidence for a specific diagnosable MDMA dependence syndrome because MDMA is typically used relatively infrequently.[38]
There are currently no medications to treat MDMA addiction.[96]
During pregnancy
MDMA is a moderately teratogenic drug (i.e., it is toxic to the fetus).[97][98] In utero exposure to MDMA is associated with a neuro- and cardiotoxicity[98] and impaired motor functioning. Motor delays may be temporary during infancy or long-term. The severity of these developmental delays increases with heavier MDMA use.[78][99] MDMA has been shown to promote the survival of fetal dopaminergic neurons in culture.[100]
Overdose
MDMA overdose symptoms vary widely due to the involvement of multiple organ systems. Some of the more overt overdose symptoms are listed in the table below. The number of instances of fatal MDMA intoxication is low relative to its usage rates. In most fatalities, MDMA was not the only drug involved. Acute toxicity is mainly caused by serotonin syndrome and sympathomimetic effects.[95] MDMA's toxicity in overdose may be exacerbated by caffeine, with which it is frequently cut in order to increase volume.[101] The estimated fatal dose of MDMA in humans is around 15 or 16 times a typical recreational dose.[102] Sympathomimetic side effects can be managed with carvedilol.[103][104] A scheme for management of acute MDMA toxicity has been published focusing on treatment of hyperthermia, hyponatraemia, serotonin syndrome, and multiple organ failure.[105]
| System | Minor or moderate overdose[106] | Severe overdose[106] |
|---|---|---|
| Cardiovascular |
| |
| Central nervous system |
||
| Musculoskeletal |
| |
| Respiratory | ||
| Urinary | ||
| Other |
|
Interactions
A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs.[58][110] MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors.[58] Life-threatening reactions and death have occurred in people who took MDMA while on ritonavir.[111] Bupropion, a strong CYP2D6 inhibitor, has been found to increase MDMA exposure with administration of MDMA.[112][113] Concurrent use of MDMA with certain other serotonergic drugs can result in a life-threatening condition called serotonin syndrome.[7][58] Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors (MAOIs),[7][58] such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix).[114] Serotonin reuptake inhibitors (SRIs) such as citalopram (Celexa), duloxetine (Cymbalta), fluoxetine (Prozac), and paroxetine (Paxil) have been shown to block most of the subjective effects of MDMA.[115] Norepinephrine reuptake inhibitors (NRIs) such as reboxetine (Edronax) have been found to reduce emotional excitation and feelings of stimulation with MDMA but do not appear to influence its entactogenic or mood-elevating effects.[115]
MDMA induces the release of monoamine neurotransmitters and thereby acts as an indirectly acting sympathomimetic and produces a variety of cardiostimulant effects.[112] It dose-dependently increases heart rate, blood pressure, and cardiac output.[112][116] SRIs like citalopram and paroxetine, as well as the serotonin 5-HT2A receptor antagonist ketanserin, have been found to partially block the increases in heart rate and blood pressure with MDMA.[112][117] It is notable in this regard that serotonergic psychedelics such as psilocybin, which act as serotonin 5-HT2A receptor agonists, likewise have sympathomimetic effects.[118][119][120] The NRI reboxetine and the serotonin–norepinephrine reuptake inhibitor (SNRI) duloxetine block MDMA-induced increases in heart rate and blood pressure.[121][112] Conversely, bupropion, a norepinephrine–dopamine reuptake inhibitor (NDRI) with only weak dopaminergic activity,[122][123] reduced MDMA-induced heart rate and circulating norepinephrine increases but did not affect MDMA-induced blood pressure increases.[112][113] On the other hand, the robust NDRI methylphenidate, which has sympathomimetic effects of its own, has been found to augment the cardiovascular effects and increases in circulating norepinephrine and epinephrine levels induced by MDMA.[112][124]
The non-selective beta blocker pindolol blocked MDMA-induced increases in heart rate but not blood pressure.[112][103][125] The α2-adrenergic receptor agonist clonidine did not affect the cardiovascular effects of MDMA, though it reduced blood pressure.[112][103][126] The α1-adrenergic receptor antagonists doxazosin and prazosin blocked or reduced MDMA-induced blood pressure increases but augmented MDMA-induced heart rate and cardiac output increases.[112][103][127][116] The dual α1- and β-adrenergic receptor blocker carvedilol reduced MDMA-induced heart rate and blood pressure increases.[112][103][104] In contrast to the cases of serotonergic and noradrenergic agents, the dopamine D2 receptor antagonist haloperidol did not affect the cardiovascular responses to MDMA.[112][128] Due to the theoretical risk of "unopposed α-stimulation" and possible consequences like coronary vasospasm, it has been suggested that dual α1- and β-adrenergic receptor antagonists like carvedilol and labetalol, rather than selective beta blockers, should be used in the management of stimulant-induced sympathomimetic toxicity, for instance in the context of overdose.[103][129]
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| SERT | 0.73–13,300 (Ki) 380–2,500 (IC50) 50–72 (EC50) (rat) |
| NET | 27,000–30,500 (Ki) 360–405 (IC50) 54–110 (EC50) (rat) |
| DAT | 6,500–>10,000 (Ki) 1,440–21,000 (IC50) 51–278 (EC50) (rat) |
| 5-HT1A | 6,300–12,200 (Ki) 126–36,000 nM (EC50) 21–64% (Emax) |
| 5-HT1B | >10,000 (Ki) 513–1,700 (EC50) 46–91% (Emax) |
| 5-HT1D | >10,000 (Ki) 51–2,630 (EC50) 28–51% (Emax) |
| 5-HT1E | >10,000 |
| 5-HT1F | ND |
| 5-HT2A | 4,600–>10,000 (Ki) 1,260–12,500 (EC50) 21–77% (Emax) |
| 5-HT2B | 269–2,000 (Ki) 126–>20,000 (EC50) 32–84% (Emax) |
| 5-HT2C | 1,550–>13,000 (Ki) 575–9,100 (EC50) 44–92% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | >10,000 |
| 5-HT6 | >10,000 |
| 5-HT7 | >10,000 |
| α1A | 6,900–>10,000 |
| α1B | >10,000 |
| α1D | ND |
| α2A | 2,532–15,000 |
| α2B | 1,785 |
| α2C | 1,123–1,346 |
| β1, β2 | >10,000 |
| D1 | >13,600 |
| D2 | 25,200 |
| D3 | >17,700 |
| D4 | >10,000 |
| D5 | >10,000 |
| H1 | 2,138–>14,400 |
| H2 | >10,000 |
| H3, H4 | ND |
| M1 | >10,000 |
| M2 | >10,000 |
| M3 | 1,850–>10,000 |
| M4 | 8,250–>10,000 |
| M5 | 6,340–>10,000 |
| nACh | >10,000 |
| TAAR1 | 250–370 (Ki) (rat) 1,000–1,700 (EC50) (rat) 56% (Emax) (rat) 2,400–3,100 (Ki) (mouse) 4,000 (EC50) (mouse) 71% (Emax) (mouse) 35,000 (EC50) (human) 26% (Emax) (human) |
| I1 | 220 |
| σ1, σ2 | ND |
| Notes: The smaller the value, the more avidly the drug binds to the site. Proteins are human unless otherwise specified. Refs: [130][131][18][132][133][134][135] [136][137][138][139][140][141] | |
MDMA is an entactogen or empathogen, as well as a stimulant, euphoriant, and weak psychedelic.[18][142] It is a substrate of the monoamine transporters (MATs) and acts as a monoamine releasing agent (MRA).[18][143][144][145] The drug is specifically a well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA).[18][143][144][145] To a lesser extent, MDMA also acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[18][143][144] MDMA enters monoaminergic neurons via the MATs and then, via poorly understood mechanisms, reverses the direction of these transporters to produce efflux of the monoamine neurotransmitters rather than the usual reuptake.[18][146][147][148][149] Induction of monoamine efflux by amphetamines in general may involve intracellular Na+ and Ca2+ elevation and PKC and CaMKIIα activation.[146][147][148] MDMA also acts on the vesicular monoamine transporter 2 (VMAT2) on synaptic vesicles to increase the cytosolic concentrations of the monoamine neurotransmitters available for efflux.[18][143] By inducing release and reuptake inhibition of serotonin, norepinephrine, and dopamine, MDMA increases levels of these neurotransmitters in the brain and periphery and thereby indirectly activates the receptors of these neurotransmitters.[18][143][149] There are species differences in the balance of MAT activities of MDMA, with it showing greater influence on serotonin in rodents than in humans.[149]
In addition to its actions as an SNDRA, MDMA directly interacts with a number of monoamine and other receptors.[18][130][131][133][132] With varying potencies ranging from high to low, it is a partial agonist of several of the serotonin 5-HT1 receptors, including the serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptors, and is a partial agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[18][132][150][151][152] The drug also interacts with α2-adrenergic receptors, with the sigma σ1 and σ2 receptors, with the imidazoline I1 receptor, and with other targets.[18][130][131][132][133] Along with the preceding receptor interactions, MDMA is a potent partial agonist of the rodent trace amine-associated receptor 1 (TAAR1).[139][140] Conversely however, due to species differences, it is far weaker in terms of potency as an agonist of the human TAAR1.[18][139][140][153] The drug appears to act as a weak partial agonist of the human TAAR1 rather than as an efficacious agonist.[139][140] In relation to the preceding findings, MDMA has been said to be essentially inactive as a human TAAR1 agonist.[18] TAAR1 activation is thought to auto-inhibit and constrain the effects of amphetamines that possess TAAR1 agonism, for instance MDMA in rodents.[143][154][155][134][156]
Elevation of serotonin, norepinephrine, and dopamine levels by MDMA is believed to mediate most of the drug's effects, including its entactogenic, stimulant, euphoriant, hyperthermic, and sympathomimetic effects.[18][143][157][67] The entactogenic effects of MDMA, including increased sociability, empathy, feelings of closeness, and reduced aggression, are thought to be mainly due to induction of serotonin release.[67][115][19] The exact serotonin receptors responsible for MDMA's entactogenic effects are unclear, but may include the serotonin 5-HT1A receptor,[158] 5-HT1B receptor,[159] and 5-HT2A receptor,[160] as well as 5-HT1A receptor-mediated oxytocin release and consequent activation of the oxytocin receptor.[18][67][161][162][142][149] The role of oxytocin in the effects of MDMA was demonstrated in people with arginine vasopressin deficiency (central diabetes insipidus), who have oxytocin deficiency and in whom MDMA fails to elevate oxytocin levels and shows greatly blunted entactogenic effects.[121][163][164] Induction of dopamine release is thought to be importantly involved in the stimulant and euphoriant effects of MDMA,[149][18][150][165] while induction of norepinephrine release and serotonin 5-HT2A receptor stimulation are believed to mediate its sympathomimetic effects.[112][143] Activation of serotonin 5-HT1B and 5-HT2A receptors is also thought to be involved in the stimulant and euphoriant effects of MDMA, while serotonin 5-HT2C receptor activation is thought to constrain these effects and limit MDMA's reinforcing potential.[149][166][167][168][169][170][171] Serotonin 5-HT2B receptor signaling appears to be required for MDMA-induced serotonin release and effects.[149][172][173][174][175][176] MDMA has been associated with a unique subjective "magic" or euphoria that few or no other known entactogens are said to fully reproduce.[177][178] The mechanisms underlying this property of MDMA are unknown, but it has been theorized to be due to a specific mixture and balance of pharmacological activities, including combined serotonin, norepinephrine, and dopamine release and direct serotonin receptor agonism.[179][177][178][180]
MDMA is often said to have mild or weak psychedelic effects.[181][115][19][182] These effects are said to be dose-dependent, such that greater hallucinogenic effects are produced at higher doses.[181][183] The mild hallucinogenic effects of MDMA include perceptual changes like intensification of visual, auditory, and tactile perception (e.g., brightened colors), a state of dissociation with feelings of depersonalization and derealization (e.g., "oceanic boundlessness"), and thinking disturbances.[181][23][115][182][117][184][183] Conversely, overt hallucinations do not occur, MDMA's hallucinogenic effects are described as "non-problematic" for users, and are said to be much less than those of 3,4-methylenedioxyamphetamine (MDA) or especially those of fully effective serotonergic psychedelics like psilocybin.[23][117][19] The hallucinogenic effects of MDMA have been theorized to be mediated by serotonin 5-HT2A receptor activation analogously to the case of classical psychedelics.[181][117][183][185][23][17] Accordingly, the serotonin 5-HT2A receptor antagonist ketanserin has been reported to reduce MDMA-induced perceptual changes in humans.[181][115][117][183] Conversely however, it failed to affect MDMA-induced feelings of dissociation and oceanic boundlessness.[181][115][183] In contrast, the serotonin reuptake inhibitor citalopram, which blocks MDMA-induced serotonin release, diminished all of the psychoactive and hallucinogenic effects of MDMA.[181][115][184][117] It has been noted that N-methylation of psychedelic phenethylamines, as in the structural difference between MDA and MDMA, has invariably greatly reduced or abolished their psychedelic activity.[186][187] Whereas MDA and psychedelics like psilocybin induce the head-twitch response in rodents, a behavioral proxy of psychedelic effects, findings on MDMA and the head-twitch response are mixed and conflicting.[188][189][190][115] In addition, whereas MDA fully substitutes for psychedelics like LSD and DOM in rodent drug discrimination tests, MDMA does not do so, nor do psychedelics generally fully substitute for MDMA.[191][115][192][193]
Long-term repeated activation of serotonin 5-HT2B receptors by MDMA is thought to result in increased risk of organ complications such as valvular heart disease (VHD) and primary pulmonary hypertension (PPH).[194][195][118][196][179][197] MDMA has been associated with serotonergic neurotoxicity.[198][19][199] This may be due to formation of toxic MDMA metabolites and/or induction of simultaneous serotonin and dopamine release, with consequent uptake of dopamine into serotonergic neurons and breakdown into toxic species.[198][19][199] Serotonin 5-HT2 receptor agonists or serotonergic psychedelics may potentiate the neurotoxicity of MDMA.[22][200][201][202]
MDMA is a racemic mixture of two enantiomers, (S)-MDMA and (R)-MDMA.[150][17] (S)-MDMA is much more potent as an SNDRA in vitro and in producing MDMA-like subjective effects in humans than (R)-MDMA.[150][145][17][203] By contrast, (R)-MDMA acts as a lower-potency serotonin–norepinephrine releasing agent (SNRA) with weak or negligible effects on dopamine.[150][145][204] Relatedly, (R)-MDMA shows weak or negligible stimulant-like and rewarding effects in animals.[150][205] Both (S)-MDMA and (R)-MDMA produce entactogen-type effects in animals and humans.[150][17] In addition, both (S)-MDMA and (R)-MDMA are weak agonists of the serotonin 5-HT2 receptors.[150][165][17][151][152] (R)-MDMA is more potent and efficacious as a serotonin 5-HT2A and 5-HT2B receptor agonist than (S)-MDMA, whereas (S)-MDMA is somewhat more potent as an agonist of the serotonin 5-HT2C receptor.[150][165][17] Due to it being a more potent serotonin 5-HT2A receptor agonist than (S)-MDMA, (R)-MDMA has been hypothesized to have greater psychedelic effects than (S)-MDMA or racemic MDMA.[206][17] However, this proved not to be the case in a direct clinical comparison of (R)-MDMA, (S)-MDMA, and racemic MDMA, with equivalent hallucinogen-like effects instead found between the three interventions.[206][17]
MDMA produces MDA as a minor active metabolite.[106] Peak levels of MDA are about 5 to 10% of those of MDMA and total exposure to MDA is almost 10% of that of MDMA with oral MDMA administration.[106][195] As a result, MDA may contribute to some extent to the effects of MDMA.[106][185] MDA is an entactogen, stimulant, and weak psychedelic similarly to MDMA.[19] Like MDMA, it acts as a potent and well-balanced SNDRA and as a weak serotonin 5-HT2 receptor agonist.[145][151][152] However, MDA shows much more potent and efficacious serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonism than MDMA.[165][185][152][151] Accordingly, MDA produces greater psychedelic effects than MDMA in humans[19] and might particularly contribute to the mild psychedelic-like effects of MDMA.[121][185] On the other hand, MDA may also be importantly involved in toxicity of MDMA, such as cardiac valvulopathy.[207][195][151]
The duration of action of MDMA (3–6 hours) is much shorter than its elimination half-life (8–9 hours) would imply.[121][208] In relation to this, MDMA's duration and the offset of its effects appear to be determined more by rapid acute tolerance rather than by circulating drug concentrations.[121][41] Similar findings have been made for amphetamine and methamphetamine.[209][210][211][212] One mechanism by which tolerance to MDMA may occur is internalization of the serotonin transporter (SERT).[213][214][215][216][217] Although MDMA and serotonin are not significant TAAR1 agonists in humans, TAAR1 activation by MDMA may result in SERT internalization, for instance in rodents in whom MDMA is a potent TAAR1 agonist.[216][217]